Please assess the completion status of the following clinical trial:

Trial Title: A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 18 years or older at time of informed consent with non-malignant chronic pain experiencing opioid-induced constipation~* Subjects with \< 3 spontaneous bowel movements a week and experiencing bowel symptoms~* Subjects receiving chronic opioid therapy due to non-malignant pain for ≥ 3 months~Exclusion Criteria:~* Evidence of clinically significant gastrointestinal disease~* History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation~* Severe constipation that has not been appropriately managed such that the subject is at immediate risk of developing serious complications of constipation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo orally once daily for 28 days.
- Naldemedine 0.1 mg (Type: EXPERIMENTAL): Participants received 0.1 mg naldemedine orally once daily for 28 days.
- Naldemedine 0.2 mg (Type: EXPERIMENTAL): Participants received 0.2 mg naldemedine orally once daily for 28 days.
- Naldemedine 0.4 mg (Type: EXPERIMENTAL): Participants received 0.4 mg naldemedine orally once daily for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).